|
WO2021076991A1
|
|
Compositions and methods for treating blood disorders
|
|
WO2020092937A1
|
|
Compositions and methods for treating brain injury
|
|
AU2017299579A1
|
|
Compositions and methods for treating frontotemporal dementia
|
|
EP3454902A1
|
|
Anti-complement factor c4/c4b antibodies and uses thereof
|
|
CN109475625A
|
|
For treating the composition and method of myeloid muscular dystrophy
|
|
WO2017091719A1
|
|
Anti-complement factor c1q fab fragments and uses thereof
|
|
CN107207587A
|
|
Humanization anticomplement factor C1Q antibody and its application
|
|
US2017081700A1
|
|
Methods for screening for inhibitors of complement serine proteases
|
|
AU2014287221A1
|
|
Anti-complement factor C1q antibodies and uses thereof
|
|
US2016090425A1
|
|
Anti-complement factor c1s antibodies and uses thereof
|
|
EP2983710A1
|
|
Methods of treatment for neuromyelitis optica
|
